MOONLAKE IMMUNOTHERAPEUTICS (MLTX)
KY61559X1045 - Common Stock
MLTX Makes Notable Cross Below Critical Moving Average
MoonLake Immunotherapeutics (MLTX) Shares Cross Below 200 DMA
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics...
Bullish Two Hundred Day Moving Average Cross - MLTX
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024.
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA...
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions ...
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
The company tested its psoriatic arthritis drug over 24 weeks against Humira.
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at...
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting...
Notable Two Hundred Day Moving Average Cross - MLTX
MoonLake gets FDA, EMA feedback on Phase 3 study (NASDAQ:MLTX)
MoonLake (MLTX) said it has received feedback from the FDA and EMA on its proposed Phase 3 study for its drug sonelokimab in the treatment of hidradenitis suppurativa. Read more.
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK)...
MoonLake Immunotherapeutics GAAP EPS of -$0.18 beats by $0.04 (NASDAQ:MLTX)
MoonLake Immunotherapeutics reports Q3 2023 financial results, with a GAAP EPS of -$0.18 beating estimates by $0.04.
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the...
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements.
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled...
Stifel starts MoonLake at buy, views lead drug as attractive M&A target (MLTX)
Stifel initiated coverage of MoonLake (MLTX) with a buy rating, stating that it sees its lead drug sonelokimab as a potential acquisition target. Read more here.